The statement, developed through a Delphi consensus process, brings together experts from clinical medicine, gastroenterology, microbiology, bioinformatics, epidemiology and related disciplines. Delphi studies use repeated rounds of structured consultation to identify areas of agreement among specialists. In this case, the goal was not to impose a single experimental protocol, but to establish a common foundation that can make clinical microbiome studies more interpretable, reproducible and useful for patient care.

Microbiome research examines the communities of microorganisms living in and on the human body, particularly the bacteria, archaea, fungi, viruses and microbial genes found in the gastrointestinal tract. These organisms can influence immune activity, metabolism, intestinal barrier function and drug processing. Yet the composition of the microbiome can change dramatically according to diet, medication exposure, age, geography, stool transit time, illness severity and the method used to collect and store samples. Without detailed information about these factors, researchers may mistake a consequence of disease or treatment for a microbial cause.

The consensus statement therefore emphasizes the importance of recording clinical metadata alongside biological samples. Such metadata can include the participant’s diagnosis, disease duration, symptom profile, comorbidities, age, sex, nutritional status and relevant laboratory measurements. Medication history is also critical, particularly recent exposure to antibiotics, proton-pump inhibitors, laxatives, immunosuppressive drugs and other treatments known to alter microbial communities. Recording these variables allows investigators to distinguish disease-associated microbial patterns from changes driven by therapy or other clinical circumstances.

Lifestyle and sampling information can be equally decisive. Dietary intake, alcohol consumption, smoking, physical activity and recent infections may all affect microbial composition. The timing of sample collection, the interval since the last meal or bowel movement, stool consistency and the conditions used for transport and storage can influence the resulting molecular profile. The statement supports consistent documentation of these details because even small differences in pre-analytical handling can create apparent biological differences between study groups.

The authors also focus on the need for clearly defined clinical end points. A microbiome study may report changes in bacterial diversity or the abundance of a particular organism, but these measurements are not automatically meaningful to patients. Clinical end points should be specified in advance and linked to outcomes such as symptom improvement, disease remission, treatment response, relapse, hospitalization, complications or survival, depending on the condition being studied. Patient-reported outcomes and validated disease activity scores can provide information that sequencing data alone cannot capture.

This distinction is technically important because microbiome measurements are often treated as surrogate markers. A shift in alpha diversity, which describes richness and evenness within a sample, or beta diversity, which compares community composition between samples, may indicate that the microbiome has changed. However, a statistically significant change does not prove that the change is clinically beneficial, harmful or causally involved in disease. Connecting microbial features to robust clinical end points is essential if microbiome research is to move beyond association studies and support diagnostics, prognostic tools or therapeutic decisions.

The consensus further highlights the importance of describing laboratory and computational methods in sufficient detail. Researchers may use 16S ribosomal RNA gene sequencing to profile bacterial communities, shotgun metagenomic sequencing to examine the broader microbial genetic repertoire, or metatranscriptomics and metabolomics to investigate microbial activity and biochemical products. Each approach has different strengths and limitations. Primer selection, sequencing depth, reference databases, quality-control procedures, taxonomic classification and statistical pipelines can all affect the conclusions. Transparent reporting would make it easier to reproduce findings and evaluate why studies disagree.

For clinical translation, standardization also matters when studies compare samples across hospitals, countries or time periods. A shared minimum data set can support better integration of cohorts and improve the statistical power needed to identify reliable microbial signatures. It may also help researchers evaluate whether a proposed biomarker performs consistently in different populations rather than reflecting a local diet, laboratory workflow or prescribing pattern. The statement does not eliminate the need for specialized information in individual diseases, but provides a baseline upon which disease-specific protocols can be built.

The authors present the recommendations as a practical framework for improving the quality of future microbiome investigations. Their central message is that a stool sample, blood specimen or sequencing file cannot be interpreted in isolation: its scientific value depends on the clinical context, the collection process and the outcome against which it is measured. By encouraging multidisciplinary collaboration and more complete reporting, the consensus aims to narrow the gap between rapidly advancing microbiome science and dependable clinical evidence. If adopted widely, these minimum standards could make results easier to compare, strengthen validation studies and help determine which microbial discoveries genuinely matter for human health.

Subject of Research: Clinical metadata and end points in human microbiome studies

Article Title: Multidisciplinary Delphi consensus statement on minimal standards for clinical metadata and end points in microbiome studies

Article References: Schierwagen, R., Carraturo, F., Iyappan, A. et al. Multidisciplinary Delphi consensus statement on minimal standards for clinical metadata and end points in microbiome studies. Nature Reviews Gastroenterology & Hepatology (2026). https://doi.org/10.1038/s41575-026-01229-1

Image Credits: AI Generated

DOI: 10.1038/s41575-026-01229-1

Keywords: microbiome, clinical metadata, Delphi consensus, gastroenterology, microbiota, clinical end points, sequencing, reproducibility, precision medicine

At the heart of this research pursuit, a groundbreaking study led by Professor Till Strowig at the Helmholtz Centre for Infection Research (HZI) has delved into the oxygen tolerance mechanisms of Segatella copri, arguably one of the most widespread human gut commensals on the planet. Oxygen availability in the gut is a pivotal environmental factor determining bacterial survival. Unlike human cells that rely heavily on oxygen for metabolism, many gut bacteria inhabit largely anaerobic conditions where oxygen presence is minimal or absent. Some bacteria strictly avoid oxygen due to its toxicity, while others can tolerate or even utilize low oxygen levels. Understanding the specific oxygen sensitivities of Segatella copri is thus vital to unraveling its ecological niche and evolutionary success.

The researchers began their investigations by exposing various strains of Segatella copri to controlled oxygen concentrations and measuring survival rates. For comparison, they included the intestinal commensal Bacteroides thetaiotaomicron, well-known for its robust oxygen tolerance. Results revealed an astonishing disparity: the survival rate of Segatella copri under oxygenated conditions was approximately 100,000 times lower than that of Bacteroides species. This profound oxygen sensitivity posed a paradox—how could Segatella copri dominate the gut flora in traditional populations where exposure to oxygen fluctuations might occur?

Seeking answers, the scientists probed the genetic responses of Segatella copri under oxygen stress through transcriptome analyses, a powerful method that identifies which genes become activated or suppressed in response to environmental challenges. Their analysis pinpointed the transcription regulator PerR, a genetic master switch previously known to orchestrate bacterial defenses against oxidative stress. PerR controls an intricate network of genes that help bacteria detect and mitigate oxygen-induced damage. Subsequent in vivo studies using mouse models underscored PerR’s critical role; Segatella copri strains lacking functional PerR failed to colonize the gut effectively, highlighting PerR’s integral function for survival and colonization under fluctuating oxygen conditions.

Interestingly, further genetic surveys conducted by the research team uncovered a surprising degree of heterogeneity at the strain level within Segatella copri populations. They explored hundreds of genomes to identify presence or absence of other oxygen response regulators, especially focusing on OxyR—another well-characterized transcription factor known to mediate adaptive responses to oxidative stress in various bacteria, including Bacteroides species. Remarkably, while some strains of Segatella copri possessed OxyR, the original strains tested lacked this gene. Hypothesizing that OxyR presence confers enhanced oxygen resilience, the scientists specifically re-examined strains containing this regulator.

The subsequent experiments validated their theory: Segatella copri strains harboring OxyR demonstrated oxygen tolerance levels 100 to 1,000-fold higher than strains without it. This discovery suggests that horizontal gene transfer—a process where bacteria exchange genetic material across species boundaries—likely introduced the OxyR gene into certain Segatella copri lineages thousands of years ago. Such lateral gene transfer events represent a fundamental evolutionary mechanism enabling bacteria to rapidly acquire new traits that favor survival in challenging environments.

Extending these findings to a global scale, the researchers collaborated with computational biologists at the University of Trento to map the geographic distribution of OxyR-positive and OxyR-negative Segatella copri strains within the human microbiome. Comprehensive genomic analyses revealed a striking biogeographic pattern: OxyR-positive strains are predominantly found in populations from industrialized countries, while OxyR-negative strains remain more prevalent in African and many Asian populations with traditional lifestyles. This pattern points towards local selective pressures shaping gut microbial communities in relation to oxygen exposure and lifestyle factors such as antibiotic use and hygiene standards.

The study postulates that in highly industrialized environments, where antibiotic consumption is frequent and perturbations to the gut microbiota are common, oxygen availability in the gut temporarily increases due to disrupted microbial ecosystems. Under these conditions, possessing robust oxygen defense mechanisms like OxyR provides a distinct survival advantage. Moreover, heightened hygiene and sanitation norms in industrialized societies potentially limit direct microbial transmission between individuals. In this context, improved oxygen tolerance may aid the bacterium’s survival outside the host during transmission, enhancing its colonization success despite environmental challenges.

This landmark research elegantly illustrates how strains within a single bacterial species can exhibit profoundly different genetic architectures and physiological traits, impacting their ability to adapt and thrive under varying environmental constraints. This intra-species diversity has far-reaching implications for understanding host-microbe interactions, microbial ecology, and potential therapeutic strategies targeting the microbiome.

Moving forward, Professor Till Strowig’s team aims to probe the health impacts of colonization by Segatella copri strains with or without OxyR, seeking to elucidate links between strain-specific microbial traits, gut ecosystem dynamics, and human health outcomes. Such insights could pave the way for microbiome-informed interventions tailored to individual microbial profiles shaped by geography and lifestyle.

Beyond microbiology, this work exemplifies the power of integrating experimental microbiology, genomics, and computational biology to unravel complex biological phenomena. It underscores the dynamic, adaptive nature of the gut microbiome and its intricate relationship with human hosts and their environments—a frontier with profound biomedical potential.

The findings were published in the prestigious journal Cell Host & Microbe, highlighting the global scientific community’s recognition of the significance of microbial strain-level diversity and gene transfer in shaping human health.

Subject of Research: Cells
Article Title: Biogeography-associated emergence of enhanced oxygen tolerance in the abundant human gut commensal Segatella copri
References: 10.1016/j.chom.2026.04.006
Web References: https://www.helmholtz-hzi.de/en
Keywords: Human gut microbiota, Microbiome, Segatella copri, Oxygen tolerance, Transcription regulators, PerR, OxyR, Horizontal gene transfer, Gut colonization, Microbial ecology

Mucus has long been recognized merely as a physical barrier protecting mucosal surfaces, yet this research underscores mucus’s biochemical arsenal against pathogenic invaders. Central to this defense are mucins, specifically the bottlebrush-shaped polymers composed of a peptide backbone densely decorated with complex sugar structures known as glycans. The study reveals that mucins are not passive shields but active modulators that influence bacterial gene expression critical for infection.

Focusing on MUC2, a prominent mucin in the intestinal tract, the researchers demonstrated its ability to suppress the expression of Salmonella’s Type 3 Secretion System (T3SS). This system constitutes a sophisticated molecular syringe that the pathogen uses to inject virulence proteins into host cells, facilitating infection and colonization. The inhibition of T3SS effectively disarms the bacterium’s invasive machinery, preventing host cell penetration and subsequent disease manifestation.

The key to MUC2’s suppressive function lies in its interaction with HilD, a master regulatory protein within Salmonella that orchestrates the activation of T3SS genes located on the Salmonella Pathogenicity Island 1 (SPI-1). When exposed to MUC2, HilD’s regulatory capacity is impeded, thus halting the production of these virulence factors. This molecular switch-off mechanism illustrates an elegant facet of innate immunity residing within mucosal secretions.

In an innovative combination of experimental microbiology and computational modeling, the team further elucidated how specific monosaccharide components of mucin glycans, such as N-acetylglucosamine (GlcNAc) and N-acetylgalactosamine (GalNAc), interact with HilD at a defined binding site. However, these sugars alone are insufficient to repress HilD’s activity; the glycans’ tethering to the peptide backbone of the mucins is essential, highlighting the structural complexity required for effective pathogen modulation.

The scope of this mucin-mediated inhibition extends beyond the intestines. Another mucin, MUC5AC—primarily found lining the stomach—exhibits a similar capacity to inhibit HilD, suggesting a conserved defense strategy across different sections of the gastrointestinal tract. Furthermore, the effect is not limited to Salmonella but also impacts other foodborne pathogens that utilize analogous gene regulation systems, potentially broadening the protective implications of mucins.

Beyond uncovering nature’s defense strategy, the MIT researchers envision harnessing this mechanism to engineer synthetic mucins. These biomimetic polymers could augment the body’s own defenses, offering an innovative line of defense against gastrointestinal infections. Synthetic mucins might be administered in conjunction with oral rehydration salts to enhance their therapeutic efficacy or formulated into prophylactic chewable tablets to preempt infection in high-risk populations, such as travelers to endemic regions.

This synthetic approach echoes nature’s evolutionary design of mucus as part of the innate immune system, aiming not just to heal but to prevent infection proactively. By bolstering mucus barriers in vulnerable regions of the gastrointestinal tract, where natural mucus layers may be thin or absent, it may be possible to curtail the initial colonization and invasion steps of Salmonella and other bacterial pathogens.

Such intervention strategies hold the potential to substantially reduce the global burden of diarrheal disease, which is a leading cause of morbidity and mortality worldwide, particularly in developing countries. This innovative biomedical avenue could alleviate billions in healthcare costs and improve productivity by preventing illness through an accessible, low-cost prophylactic formulation.

The implications extend well into biodefense and public health domains, where rapid deployment of synthetic mucin-based products could protect soldiers, emergency workers, and populations exposed to contaminated environments. This breakthrough exemplifies how fundamental biological insights can translate into tangible health innovations.

The research, led by Professor Katharina Ribbeck and her team at MIT, involved lead authors Kelsey Wheeler and Michaela Gold, and was recently published in the journal Cell Reports. The study was supported by prominent institutions including the U.S. Army Research Office, the U.S. National Science Foundation, and the German Research Foundation, underlining the significance and collaborative nature of this work.

In summary, this research fundamentally advances our understanding of mucosal immunity by illuminating how mucus-derived glycans serve as molecular signals that incapacitate Salmonella infection machinery. It opens new horizons for preventive medicine through the bioengineering of mucin mimics—a strategy grounded in harnessing the body’s own evolutionary defense.

Subject of Research: Interaction of mucus-derived mucins with Salmonella Typhimurium to inhibit bacterial invasion through repression of SPI-1 gene expression.

Article Title: Mucus-derived glycans are inhibitory signals for Salmonella Typhimurium SPI-1-mediated invasion

News Publication Date: 23-Sep-2025

Web References: https://www.cell.com/cell-reports/fulltext/S2211-1247(25)01075-7

References: DOI: 10.1016/j.celrep.2025.116304

Image Credits: MIT

Keywords: Bioengineering, Mucus, Organismal biology, Life sciences, Diseases and disorders, Diarrhea, Symptomatology

The newly developed device, known as the CORAL (Cellularly Organized Repeating Lattice) capsule, has been engineered by Khalil Ramadi, an assistant professor of bioengineering at New York University Tandon School of Engineering and NYU Abu Dhabi, in collaboration with his colleagues. This capsule represents the first passive, non-invasive method for collecting microbial samples from the upper digestive tract. Upon ingestion, the capsule navigates the digestive system, trapping bacteria along its journey before ultimately being expelled from the body.

In a recent study published in the journal Device, the research team demonstrated how the CORAL capsule yields a more accurate representation of the small intestine’s microbial landscape compared to traditional stool sampling, which currently serves as the gold standard in microbiome research. The traditional method, while convenient, fails to capture the distinct microbial communities residing in various gut regions, particularly in the small intestine.

Khalil Ramadi emphasized the shortcomings of fecal samples, stating that although they are easy to collect, they do not accurately reflect the diverse microbial populations in specific gut regions. This discrepancy is significant because the small intestine plays a crucial role in numerous bodily functions and processes. As the body’s largest mucosal surface, the small intestine is densely populated with immune cells, receptors, and neurons, making it essential for interactions between the host and microbiome.

Emerging studies indicate that a variety of diseases, including immune system disorders, metabolic conditions, and endocrine issues, may stem from the gut, highlighting the need for a deeper understanding of the unique microbial populations that inhabit the small intestine. These microbes are believed to have distinct metabolic functions and immune roles that differ substantially from their counterparts in the large intestine, making their study vital for developing effective therapeutic interventions.

The CORAL capsule addresses a significant knowledge gap in microbiome science by providing access to previously unreachable bacterial communities. Aashish Jha, an Assistant Professor of Biology at NYUAD and co-senior author of the study, pointed out that understanding these upstream microbial populations may be key in diagnosing diseases early and devising targeted treatments. The implications of this technology are vast, with the potential for enhancing health outcomes through tailored microbiome interventions.

Engineered to mimic marine corals, the CORAL capsule employs a unique design based on Triply Periodic Minimal Surfaces (TPMS), which creates a complex network of labyrinthine channels. These channels are scientifically optimized to trap bacteria while allowing the capsule to safely maneuver through the digestive tract. This innovative design ensures that bacteria from the small intestine can be collected effectively.

What sets the CORAL capsule apart from existing microbiome sampling devices is its entirely passive operation. Unlike previous devices that depend on magnets, mechanical parts, or electronic components to function, CORAL relies solely on the structural design and the natural movement of the gut to facilitate bacterial sampling. Furthermore, the capsule is created in a single step using advanced 3D printing technology, ensuring scalability for potential widespread implementation. A specialized coating enables the capsule to commence sampling only upon reaching the small intestine, thereby preventing contamination by stomach acids.

Hanan Mohammed, the study’s lead author and a Research Associate at NYUAD, noted the simplicity of the capsule’s design, stating that it requires no batteries or electronic components. This makes it an appealing alternative to more complex devices, as it allows researchers to access bacterial communities that have, until now, remained hidden from scientific scrutiny.

Preliminary animal studies have showcased the efficacy of the CORAL capsule in capturing unique bacterial populations from the small intestine, revealing a striking divergence from what is typically found in fecal samples. In these studies, researchers discovered elevated levels of beneficial bacteria such as Lactobacillus, which thrives in the small intestine’s lower pH environment, while deliberately avoiding the types of bacteria predominantly found in the large intestine.

The development of the CORAL capsule is part of Ramadi’s broader objective to revolutionize the way diseases are diagnosed and treated by leveraging insights from the gut microbiome. His research also includes the exploration of “electroceuticals,” which are ingestible devices capable of diagnosing and addressing various conditions ranging from immune disorders to metabolic diseases by tapping into the body’s inherent neural pathways.

With aspirations of translating the CORAL capsule for human use, the research team is focused on scaling the device from its current small size to a standard pill, making it practical for clinical application. Before embarking on human trials, however, developers will need to establish reliable retrieval methods, potentially utilizing magnetic detection or other identification technologies, along with thorough safety testing to ensure the device’s compliance with medical standards.

Ongoing research within the laboratory continues to foster the translation of this innovative technology, with the team actively seeking commercialization opportunities through the HealthX program at StartAD and the Abu Dhabi Department of Health. As the potential for the CORAL capsule unfolds, it stands on the brink of becoming a transformative tool for understanding the microbiome and its implications for health, paving the way for innovative diagnostic strategies and therapeutic approaches reliant on our bodies’ intricate microbial ecosystems.

This breakthrough in microbiome research not only symbolizes a significant advancement in our understanding of the small intestine but also reflects the power of interdisciplinary collaboration in tackling profound scientific challenges. The merging of biological inspiration with cutting-edge engineering paves the way for new frontiers in medicine, offering fresh perspectives on how we can harness the potential of our own microbiomes to foster better health outcomes and improved quality of life.

Subject of Research: Microbial sampling in the human small intestine
Article Title: Passive intestinal microbiome sampling using an ingestible device with tortuous lattices
News Publication Date: 5-Sep-2025
Web References: Device Journal
References: Ramadi, K., Jha, A., & Mohammed, H. (2025). Passive intestinal microbiome sampling. Device. DOI: 10.1016/j.device.2025.100904
Image Credits: NYU Abu Dhabi

Keywords

Bioengineering, Microbiome Research, Ingestible Devices, Coral-Inspired Technology, Intestinal Health, Bacterial Sampling, Non-Invasive Diagnostics